D06FFD0C-80D4-413D-9C83-62D9C163EDAB
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.83705650459921
- age_years
- 80
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.696
- INTERFERON_GAMMA_RESPONSE+0.656
- E2F_TARGETS+0.579
- MYC_TARGETS_V1+0.560
- ALLOGRAFT_REJECTION+0.544
- DNA_REPAIR+0.511
- IL6_JAK_STAT3_SIGNALING+0.507
- INFLAMMATORY_RESPONSE+0.469
- G2M_CHECKPOINT+0.461
- OXIDATIVE_PHOSPHORYLATION+0.434
Top 10 suppressed
- KRAS_SIGNALING_DN-0.307
- HEDGEHOG_SIGNALING-0.229
- MYOGENESIS-0.152
- SPERMATOGENESIS-0.142
- PANCREAS_BETA_CELLS-0.115
- WNT_BETA_CATENIN_SIGNALING-0.069
- MITOTIC_SPINDLE-0.032
- UV_RESPONSE_DN+0.067
- HEME_METABOLISM+0.080
- APICAL_JUNCTION+0.121
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 53B31ABD-AD68-4A44-A525-23FD413115D5 | — | — | 0.972 |
| 2 | A0396799-AB5C-401F-81FF-7C829A3CF1E4 | — | — | 0.970 |
| 3 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.968 |
| 4 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.965 |
| 5 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.965 |
| 6 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.962 |
| 7 | 5307FA7F-DFE5-42BC-BFC7-826AACAAE799 | — | — | 0.960 |
| 8 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.959 |
| 9 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.956 |
| 10 | 8B4E465B-0FD5-4154-824B-1E6B2656FD2F | — | — | 0.956 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.696 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.656 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.579 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.560 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.544 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.511 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.507 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.469 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.461 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.434 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.433 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.428 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.405 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.404 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.399 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.397 | Inavolisib | — uncovered |
| COMPLEMENT | 0.391 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.391 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.382 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.378 | Remibrutinib | — uncovered |